Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III

by Kinjel Shah

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q2 earnings.

Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $110.39 in the latest trading session, marking a +1.78% move from the prior day.

Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal

by Zacks Equity Research

Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $105.57 in the latest trading session, marking a -1.65% move from the prior day.

Should ALPS (OUSA) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for OUSA

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $108.70 in the latest trading session, marking a -1.15% move from the prior day.

Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug

by Zacks Equity Research

Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

by Zacks Equity Research

Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.

Here's Why You Should Add Alkermes (ALKS) to Your Portfolio

by Zacks Equity Research

Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.

Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC

by Zacks Equity Research

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $113.54 in the latest trading session, marking a +0.98% move from the prior day.

Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Is ALPS (OUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for OUSA

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $114.60, moving +0.77% from the previous trading session.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer

by Zacks Equity Research

Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.

Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal

by Zacks Equity Research

Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.

Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study

by Zacks Equity Research

Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

by Zacks Equity Research

IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $108.66, marking a -1.21% move from the previous day.